The Productivity Commission released its final report from the inquiry into delivering quality care more efficiently. It argues that a stronger focus on prevention and early intervention can reduce lo...
New modelling from Dexcom shows publicly funded continuous glucose monitors for type 1 diabetes in New Zealand have opened access to more than 19,000 people in the first year since October 2024. The p...
The NSW branch of the Australian Medical Association released a plan to tackle illicit tobacco in New South Wales. The strategies were submitted to the NSW Legislative Council after parliamentary hear...
A major review published in Lancet Obstetrics Gynecology and Women’s Health finds no link between taking paracetamol during pregnancy and autism spectrum disorder ADHD or intellectual disability in ch...
2025 brought big shifts in cardiovascular care. Large studies challenged routine lifelong aspirin, showing the benefits do not outweigh the risks. One trial had to stop early due to excess deaths. Usi...
The United States has launched the first oral GLP-1 weight loss medicine with the approval of an oral semaglutide pill, marketed as Wegovy, by the FDA in December 2025. It is now available by prescrip...
The Productivity Commission has released the final version of Delivering quality care more efficiently. It calls for stronger formal coordination between hospitals and Primary Health Networks. It want...
A recent international study analysed over 9000 participants across 37 studies to understand the long-term effects of weight-loss medications, including GLP-1 receptor agonists. The findings show that...
The US has released new dietary guidelines for 2025–2030, marking a significant shift in nutrition policy. While these guidelines apply to Americans, their influence extends globally, including Austra...
A recent analysis in the BMJ shows that stopping weight-loss drugs, especially GLP-1 receptor agonists like semaglutide and tirzepatide, leads to quick weight regain. Patients tend to regain about 0.4...
Research from Murdoch University shows a strong link between limb injuries leading to Complex Regional Pain Syndrome (CRPS) and the development of migraines. The study involved 88 adults with CRPS in...
The Australian government is moving to list Wegovy, a weight-loss drug containing semaglutide, on the Pharmaceutical Benefits Scheme (PBS). This follows a recommendation from the Pharmaceutical Benefi...
The Australian government will start reimbursing GPs and specialists equally for ECG services from March 2026. This change follows years of lobbying by the RACGP and other health groups. The move is b...
Health Minister Mark Butler is moving to expand PBS access to GLP-1 drugs like Wegovy for obesity treatment. Currently, these medications are only subsidised for type 2 diabetes. The government is con...
The PBAC recommended listing Wegovy (semaglutide) on the PBS for adults with obesity and established cardiovascular disease. The decision targets high-risk groups, including those with a BMI of 35 or...
VicHealth will be absorbed into the Victorian Department of Health. This move has sparked concern about the future of health promotion in Australia. VicHealth has been a global symbol of prevention an...
The Australian healthcare sector saw significant policy changes in 2025. The government announced an $8.5 billion Medicare reform package in February, focusing on bulk-billing incentives and chronic d...
Researchers from Curtin University released a study showing that where people live affects their weight. They used data from the HILDA survey over 14 years to track Australians who moved between areas...
In 2025, weight-loss medications remained a top topic among Australian GPs. The government made significant MBS changes from July, affecting chronic disease and vitamin B12 testing. Semaglutide, a GLP...
